Stroke represents a major burden to patients and society, and resources spent on stroke research must be used efficiently and produce good value in terms of improvements in human health.
Introduction
The World Health Organisation has reported that stroke is the leading cause of disability among adults, and the second leading cause of death worldwide (1) . More than 33 million people worldwide have a stroke each year (2) , and in 2010 the estimated annual cost of stroke was $53.9 billion in the US and €64.1 billion in Europe (3;4) . Demographic changes caused by increase in longevity and changes in lifestyle will lead to a further increase in the burden of stroke(1;2), and research into prevention and treatment of stroke should therefore be a priority (5) . Several notable successes in stroke research have delivered substantial health benefits in the past, with associated costs savings for society, for treatments such as antithrombotic or blood pressure lowering treatment for stroke prevention, and thrombolytic drugs, intra-arterial interventions, and multidisciplinary care in stroke units for treatment in the acute phase (6) (7) (8) (9) (10) . However, despite recent modest increases in funding(5;11), stroke research remains underfunded compared to research in other major disease areas, such as cardiac disease and cancer (11;12) .
Given the limitations of resources it is all the more important that funding allocated to stroke research is used efficiently, and produces good value for money in terms of advances in knowledge or improvement in human health. A key challenge for funders of research is that
Research prioritisation
The financial and human resources available to undertake human health research are finitelimited.
Therefore, to ensure best use of resources, regulators, funders, researchers and potential research participants should work collaboratively to identify priority areas for research (16) . Many projects do not lead to notable benefits, either because they contribute little to knowledge about basic mechanisms that have relevance for human health (basic research), or to practice and policy (applied clinical research), or both (the "waste quadrant") (16;21) . Other projects contribute little because of unnecessary duplication of existing knowledge (16;21 ).
An accepted criterion for prioritisation is that the research should address a health problem that causes a significant burden to society (21) . However, resources allocated to stroke research are often not directed at yielding the greatest health benefits on a population level. For example, strategies for improved primary or secondary prevention (e.g. blood pressure lowering) are likely to yield large benefits at a population level, but are often not prioritised. Similarly, research into stroke recovery is consistently highly valued by patients and may have a large impact on strokerelated disability, but few large rehabilitation trials have been performed. Several recent initiatives have sought to improve prioritisation of health research studies. The National Institutes of Neurological Disorders and Stroke (NINDS) are leading an effort to make trial selection more explicit and rationale in its Immediate Practice-Altering Clinical Trials (ImPACT) pilot program (22) , and metrics for the public health impact of clinical trials have been developed (23) . The James Lind Alliance (24) seeks to establish priority setting partnerships for a wide range of health problems, by bringing together stakeholders to identify the most important uncertainties. Of relevance to neurology, such partnerships have been established to set research priorities for cavernous malformations, dementia, multiple sclerosis, neuro-oncology, Parkinson's disease, spinal cord injury, and stroke (25) .
Another frequently cited criterion for priority setting is that the research should be patientcentred, focussing on the aspects of the problem that people with the condition under study consider important. However, different stakeholders in research may have different priorities.
For example, funding agencies may have selected a broad thematic area (e.g. cognitive decline after stroke), yet researchers may have a very narrow scientific question (e.g. whether a particular agent prevents cognitive decline), and potential research users may value studies that addresses clinical services rather than a specific drug therapy. Care givers may have yet another view(26), and, Iimportantly, even among patient sub-groups different priorities may exist. For example, patients with stroke-related disability may be more interested in research into rehabilitation, while people who have not had a stroke, or a non-disabling stroke, may be more interested in research into prevention or acute treatment. Patients may also have different views on which outcomes are important. For example, while some will value the effect of a new treatment on cognitive function, others will prioritise social and emotional function, outcomes over the longer term, and risk of adverse reactions (27) (28) (29) . To fulfil the criteria that research should address major health problems and the needs of patients, it seems clear that priority topics must be agreed through an alliance between stakeholders, including regulators, funders, researchers, care givers and patients (16) .
While some research aim at changing practice and policy (applied clinical research), other research can contribute to knowledge about basic mechanisms that have relevance for human health (basic research) (16;21) , such as genetic mechanisms of stroke (30) . There should also be a scientific basis for evaluating a specific clinical intervention. For example, it is possible that many of the neutral or negative trials of neuroprotective agents could have been avoided, had there been a better understanding of basic mechanisms, experimental bias, and the disparities between pre-clinical models and clinical studies (31) (32) (33) , and a closer collaboration between preclinical and clinical researchers. It is alsoFinally, it is a fundamental criterion for effective research prioritisation that the question under study should not have been answered by prior research. It is therefore important that all research is preceded by a systematic review of what has already been done, to avoid unnecessary duplication, to identify what should be replicated, and to identify questions from previous work which could lead to new research (34) .
Research prioritisation exercises can themselves be wasteful of researcher time and effort. For example, although a specific EU "Horizon 2020" funding call will disburse half a dozen millions of Euros, only a few of the many applications will be funded (35) . When the total cost in research time in preparing the applications is considered, a significant amount of non-productive resource is expended by those groups whose proposals were not funded. This raises the question whether projects should be triaged at an earlier stage, or whether there can be other ways of allocating funding, for example more sustained core funding over a defined period of time to particularly skilful research groups, to allow maximum freedom of research (36) . 2. Use of systematic reviews to identify an important research topic. A Cochrane systematic review of trials of selective serotonin reuptake inhibitor after stroke showed that a large number of small trials had been conducted, which, in aggregate, suggested that a large scale trial was needed (39) . It was not feasible to obtain funding for a multinational trial, so a "federation" of three parallel trials has been established (40) , with an agreed core dataset to address mutually agreed questions. 
Research design, conduct, and analysis
Without appropriate design, conduct and analysis research is of reduced value, no matter how relevant the research question is, how efficiently the research is regulated, how widely the findings are disseminated, or how well they are reported (17) . It is therefore important that research teams are able to draw on expertise appropriate to their tasks, at every stage of the research cycle. As Ronald Fisher said, "to call in the statistician after the experiment is done may be no more than asking him to perform a post-mortem examination: he can perhaps say what the experiment died of". Because current incentives for biomedical researchers prioritise novelty and quantity over replication and quality, it is not enough simply to do work which is important and relevant. One must also be able to demonstrate that the work is of high quality.
Poor experimental design, conduct and analysis are important causes of waste in stroke research. (31) (32) (33) . Eligibility criteria may be overly complex, for example relying on invasive or complex imaging studies, restricting the pool of available patients and centres and reducing generalisability. Data collection forms may also be complex, burdening centres with a requirement to collect data items which are subsequently never analysed or reported. Overly-optimistic assumptions may be made for sample size calculations, leading to underpowered trials with inconclusive results. Important outcome measures may not be included at design phase, missing the opportunities to capture valuable information about quality of life, cognition, or costs of treatment.
Institutions, funders and stroke organisations share the responsibility for education and training of stroke researchers, to enable them to design and conduct high-quality stroke research, including pre-clinical studies, translation research, and clinical trials specific for prevention, acute treatment, and recovery of stroke. Openly accessible resources could be developed (including, for example, standard contracts, outcome assessment instruments, trial insurance information). Investment should also be made into developing and maintaining stroke research networks, to facilitate and standardise stroke research within health care systems (42) .
Research institutions should also provide core methodological expertise. To ensure high quality, researchers need to have not only content expertise (e.g. a theoretical understanding of the statistical methods used), but also experience of the practical application of this knowledge in stroke studies. Problems may arise at the design phase if such expertise is not available, and recruiting individuals with such expertise after a grant has been awarded is challenging, since by that stage much of the study design is already established. Many research groups are funded largely through income from time-limited grants, so it is only possible to retain such experienced individuals if the lead researcher repeatedly applies for grants to sustain the group. This may divert effort from addressing the most relevant research questions, and so another perverse incentive is born. An alternative model would be that research institutions on a local or regional level provide funding for individuals with core research methodological expertise, either embedded within, or accessible to, the research groups that they serve.
Finally, it is important that publishers, funders, institutions and stroke organisations reward not only researchers who produce research outputs in large quantity or on novel topics, but also those who do research to replicate key research findings, or high quality studies of treatments in clinical practice with large impact on human health. While publishers and funding agencies have an important role (by limiting access to publications and grants), it is also critical that institutions adopt a more nuanced approach to selecting candidates for promotion or tenure, with emphasis on delivery of high quality, well-designed research (following for instance the Leiden
Manifesto (43)), and that national research assessment exercises take greater account of the rigour with which research was conducted (44) . There is also insufficient academic recognition of some 
Regulation and management
Research regulation (including governance) and management is essential to ensure that trials are performed ethically for the best interest and protection of participants, and to high scientific standards, but waste can arise from excessive and complex regulation and from poor management. Overburden of regulation and governance can lead to the failure of trials to recruit to time or target, or to researchers avoiding addressing important questions because of concerns that it will not be feasible to meet regulatory requirements, resulting in unnoticed and unquantifiable waste(18;51).
Regulations for approval and conduct of research involving medical devices or drugs are complex, variably interpreted and enforced in different countries, and often out of proportion to the risk to participants (52) . For instance, the EuroHYP-1 study of therapeutic hypothermia for acute ischaemic stroke (53) has been subject to extensive delay in receiving regulatory approval, due to being inconsistently classified as a drug trial, a device trial, neither or both, across different competent authorities in Europe. Some of the regulations for drug trials, such as expedited reporting of suspected unexpected serious adverse reactions, and on-site monitoring, were developed for the testing of new agents in industry-led studies, and may not be appropriate for low-risk investigator-led trials testing licensed agents that have been in everyday clinical use for many years.
Regulations for recruitment of patients with reduced consent capacity represent a particular problem in acute stroke trials, in some cases leading to delays in recruitment because of burdensome consent processes. There is a need to find alternative and simpler ways of patient recruitment to low-risk acute stroke trials. For example, some trials have developed emergency consent processes, with brief(54) or verbal consent(55;56), or even waiver of consent (57), after approval by ethics committees. The European Commission's revised proposal for clinical trial regulation opens for a more flexible approach to consent in emergency settings (58) , and this should probably be used more often in stroke research.
Reduction in waste can also be expected from recent initiatives aiming at simplifying, centralising and harmonising regulation, and at making it proportionate to the degree of risk posed by the intervention under study. For example, the revised Declaration of Helsinki and the revised proposal for clinical trial regulation in the EU (58) During most of the course of the MR CLEAN trial of intra-arterial treatment for acute ischaemic stroke, the costs of treatment were only reimbursed for patients included into the trial(64), which was important for the trial's ability to deliver to time and target. 
Accessibility of information
Much research never gets published(20;80), and access is restricted to subscribing institutions for many of the journal reports that are published. Furthermore, journal reports represent only a fraction of the information from a study, and the selection of which studies to report, and what information to share from each study, is often biased. Valuable information is also contained in research protocols, and more detailed analysis of participant-level data can be of great value, to verify the original findings, to answer new questions, or to plan new research. Accessibility of research protocols, primary journal reports, full study reports and availability of individual participant data will therefore increase value of research, and can reduce waste by avoiding redundant, misguided or even harmful research being done (19) . Trials produce many more data than presented in a single article, and data selected for presentation in the primary report can be biased. For example, the study protocol and the statistical analysis plan contain data that are essential to the correct interpretation of the trial's results. Unexpected challenges can arise, and plans often need to be changed for good reasons (e.g. change in inclusion criteria, change in sample size requirements due to unexpected outcome event rates, change in analysis method), but such changes need to be apparent rather than hidden.
However, study protocols and statistical analysis plans are often not generally accessible, and when these can be accessed, even items as critical as eligibility criteria for inclusion into the trial were found to differ frequently between the study protocol and the published article(83;84). Such selective reporting can amplify the bias arising from selective reporting of entire studies (19) , and is a possible explanation why the results often cannot be independently replicated. Suspicion of selective reporting can also be a reason for distrust in trial results, even for treatments of which benefits are considered beyond reasonable doubt by the majority of clinicians, such as thrombolysis for acute ischaemic stroke (85) . One solution could be to require the publication of the study protocol after registration (83;84) or, if this is not feasible, through registration at for example the Open Science Framework (86) .
Even when studies are reported, access to research is restricted, due to costs of journal subscriptions, or language barriers. "Open access" publishing represents a step forward, but is still not widely used (87) The problem of reporting bias can perhaps be reduced by mandating the sharing of individual participant data from clinical trials, as proposed by the ICMJE and increasingly demanded by research funders and publishers (19;88;89) . Data sharing will allow verification of the published results and detection of errors (19) , which can increase confidence in results. It can also be used to examine new research questions, particularly if data from different trials can be pooled, and to plan new trials, for example in sample size calculations.
Obviously, specific conditions must be met to support the widespread sharing of individual participant data (88;90) . Participants' anonymity must be preserved, and investigators should receive academic credit for sharing their data, from funders, publishers and institutions. They should also have the opportunity to publish any pre-specified analyses before giving access to others, and they should be included in publications arising from analysis of data that they have collected (91) . It is also important that data is collected in standard formats to allow their integration, and that data are accompanied by clear metadata to avoid misinterpretation. There is also a need for standardised repositories where data can be uploaded and curated, such as the Virtual International Stroke Trials Archive (VISTA)(92;93).
There are several initiatives aiming at making research information available. The AllTrials campaign has proposed that "all trials past and present should be registered, and the full methods and the results reported" (94) . The Linked Clinical Trial project (95) is an independent membership association, founded and directed by publishers, that connects users to all published material related to an individual clinical trial. ClinicalTrials.gov also allows for links to protocols and full study reports, including data that were not included in the published report (96) . Center for Open Science allows researchers to organise and archive research material and data, and later make these publicly available(97). 
Reporting
Few would dispute that reports of research should describe the question, its importance, the experimental method, the results, and the meaning of the results(109). Research will be wasteful if information is inadequate to be able to interpret the results correctly, to plan new research based on what has already been done, and to replicate research. Reporting guidelines aim to improve the quality of research reports, but they are often not adhered to. Many studies have found substantial evidence of poor research reporting, for all objectives listed above, regardless of disease, type of study, and type of publication (20) . (112) ; inadequate adherence to reporting criteria among randomisedcontrolled trials (113) ; and insufficient descriptions of interventions in trials included in systematic reviews (114) . However, it has yet to be establish the extent of adherence to reporting guidelines, the adequacy of reporting of pharmacological interventions, the selectiveness of outcome reporting (115) , and the reproducibility of findings in stroke research. (125), has already been used in a trial of functional strength straining after stroke (126) .
Conclusions and future perspectives
In this Policy View we have identified sources of waste in stroke research, and recommended approaches to reduce waste and increase value for each of the areas covered by The Lancet's series (Panel 7). Our examples of best practice illustrate that some progress has been made, but there is room for much improvement, and stroke researchers, funders and other stakeholders might consider our recommendations when planning new research.
For some of the areas (e.g. research design, accessibility and reporting) there is consensus on what constitutes best practice, and what changes to practice and policy that might reduce waste.
However, little empirical evidence exists about adherence to these practices. For example, although reporting guidelines have been made, we have no data on whether they are used for reporting of stroke studies. For other areas (e.g. research regulation, management and analysis)
there is uncertainty about what is best practice, and consensus has yet to be reached. For example, there is still many questions about the best ways to increase patient recruitment and retention (68) , and to analyse data from stroke trials (50) . In order to understand what is best practice in these areas, and to learn whether best practices are followed, we need more methodological research.
Approaches to reduce waste and increase value in stroke research must therefore include changes to practice as well as methodological research.
For the areas in which there is consensus, waste must be reduced by changes to practice, for example, stronger adherence to reporting guidelines. Just as integration of research findings into clinical practice is often slow (e.g. proven treatments), adherence to best practices in stroke research can be inadequate. Information about adherence is important, but may not be sufficient, and stroke research may benefit from the results of implementation science to foster this last, important step from consensus to change in research practice.
We have highlighted examples of best practice in stroke research in the hope that they will 
Panel 7. Take-home messages
 There is waste and reduced efficiency in the way stroke research is chosen, designed, conducted, analysed, regulated, managed, disseminated and reported. There is need for change in practice, as well as for methodological research to investigate methods of reducing waste and to monitor whether known methods of reducing waste are being followed.
 Prioritisation: Criteria for prioritisation and priority topics for stroke research should be agreed through an alliance between stakeholders, including professional and patient/carer stroke organisations. All projects should be able to demonstrate that they have considered the needs of users of research, and that they build on knowledge from previous research.
 Design, conduct and analysis: Institutions should provide education and training in research methods, and core methodological expertise. Funders should consider investing in stroke research networks, and funders, publishers and institutions should reward replication and quality of stroke research (instead of quantity alone). Stroke researchers might consider developing specific recommendations for the conduct of clinical trials in prevention, acute treatment, and recovery of stroke. Metrics could be used to check compliance with recommendations. Methodological research should be done to monitor the degree to which recommendations are followed, and to find the best research methods. Committee. Further references were identified through searches on PubMed with the terms "waste", "inefficiency", "prioritisation", "design", "conduct", "analysis", "regulation", "management", "accessibility" OR "reporting", each in combination with "stroke" AND "research". Only papers published in the period January 2010 to August 2016 were considered.
The symposium was based on The Lancet series (16) (17) (18) (19) (20) , and topics and speakers were agreed between the ESO Trials Network Committee and The Lancet Neurology editors. The survey was designed by members of the ESO Trials Network Committee.
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